Welcome to our dedicated page for AVROBIO news (Ticker: AVRO), a resource for investors and traders seeking the latest updates and insights on AVROBIO stock.
AVROBIO, Inc. (AVRO) is a clinical-stage biopharmaceutical company pioneering gene and cell therapies for rare diseases and cancer. This page aggregates official announcements, clinical trial updates, and strategic developments critical to understanding the company's progress.
Investors and researchers will find verified updates on therapy pipelines, regulatory milestones, and scientific collaborations. Content spans phase trial results, manufacturing advancements, and partnership announcements, providing a holistic view of AVROBIO's position in the gene therapy landscape.
All materials are sourced from company filings and accredited industry publications. Bookmark this page for streamlined access to AVROBIO's latest developments, or subscribe for real-time updates on groundbreaking therapeutic innovations.
AVROBIO, Inc. (Nasdaq: AVRO) announced the grant of 35,500 restricted stock units (RSUs) to three new employees as inducement awards under its 2019 Inducement Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and were approved by the Compensation Committee. The RSUs, awarded on Aug. 1, 2022, will vest over four years, contingent upon continued employment. AVROBIO's mission focuses on advancing gene therapy aimed at treating genetic diseases, utilizing its plato® gene therapy platform across various conditions, including cystinosis and Gaucher disease.
AVROBIO (Nasdaq: AVRO), a clinical-stage gene therapy company, announced its participation in two upcoming investor conferences:
- Hybrid BTIG Biotechnology Conference: August 8-9, 2022
- Virtual Wedbush PacGrow Healthcare Conference: Panel 'Miss ConGENEiality' on August 10, 2022, at 9:10 a.m. ET
AVROBIO aims to bring personalized gene therapy to halt or reverse genetic diseases via its plato® gene therapy platform, with programs targeting cystinosis and Gaucher disease.
AVROBIO announced that the FDA has granted orphan drug designation for AVR-RD-05, a gene therapy aimed at treating mucopolysaccharidosis type II (Hunter syndrome). This designation allows for various incentives, including tax credits and prescription drug user fee waivers. The therapy uses a patient’s own hematopoietic stem cells modified to express the missing enzyme. The planned Phase 1/2 trial in collaboration with the University of Manchester is expected to start in 2023. Hunter syndrome affects approximately 1 in 100,000 males, leading to severe health complications.
AVROBIO, a clinical-stage gene therapy company, announced the issuance of 37,500 restricted stock units (RSUs) to three new employees as part of its 2019 Inducement Plan. These awards, granted on July 1, 2022, are designed to incentivize employment acceptance and were approved by the company's Compensation Committee. The RSUs will vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal installments thereafter, contingent on continued service. AVROBIO focuses on gene therapies for genetic diseases, leveraging its proprietary plato® platform.
AVROBIO announced promising preclinical data for its AVR-RD-03 gene therapy targeting Pompe disease, showing a significant reduction in glycogen accumulation in cardiac, skeletal muscles, and the CNS in a mouse model. After eight months, glycogen levels were nearly normal in treated tissues. The therapy demonstrated stable engraftment and significant GAA enzyme activity, crucial for combating this life-limiting disorder. AVROBIO plans to initiate clinical trials in 2023, following positive results that suggest a potential breakthrough in treating Pompe disease.
AVROBIO (NASDAQ: AVRO) reported promising interim data from a Phase 1/2 clinical trial of AVR-RD-04, a gene therapy for cystinosis, showing stabilized or improved visual motor integration and coordination in five patients. All patients remain off oral cysteamine following treatment. The therapy demonstrated a favorable safety profile with no related adverse events. Key findings indicate a systemic distribution of functional cystinosin and reductions in cystine crystal accumulation in multiple tissues. A company-sponsored trial is planned for 2023, following positive proof-of-concept results.
AVROBIO, a clinical-stage gene therapy company, announced its senior management will present virtually at the H.C. Wainwright Global Investment Conference from May 23-25, 2022. A pre-recorded presentation will be available from May 24 at 7:00 AM ET on the AVROBIO website, archived for 30 days. AVROBIO's goal is to deliver innovative gene therapy solutions aimed at genetic diseases, leveraging its plato® platform. The company is headquartered in Cambridge, Mass..
AVROBIO announced the full enrollment of its Phase 1/2 clinical trial for the first gene therapy treatment for cystinosis. New interim data is expected to be presented at the ASGCT annual meeting from May 16-19, 2022. The company plans multiple regulatory engagements this year for various gene therapy programs, maintaining a strong financial position with $161.7 million in cash, expected to fund operations through Q1 2024.
AVROBIO, Inc. (NASDAQ: AVRO) has granted stock options for 63,000 shares and 67,177 restricted stock units (RSUs) to new employees as part of its 2019 Inducement Plan. The options were priced at $0.93 per share and vest over four years, with a quarter vesting on the first anniversary and the remainder monthly. The RSUs follow a similar vesting schedule. These inducement grants were approved by the Compensation Committee, as per Nasdaq Listing Rule 5635(c)(4). AVROBIO is focused on gene therapy aimed at treating genetic diseases.
AVROBIO, Inc. (NASDAQ: AVRO) has announced new data from its ongoing Phase 1/2 clinical trial for cystinosis, which will be presented on May 16, 2022, at the 25th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, D.C. Dr. Stephanie Cherqui will present updated results from patients dosed with AVR-RD-04, an investigational gene therapy. Additionally, preclinical data for the Pompe disease program will be shared by Dr. Niek van Til on May 18. AVROBIO aims to advance gene therapy to treat genetic diseases effectively.
